Russian drugmaker Polysan will invest about 4 billion roubles (~$60 million) in the establishment of… To continue reading The Pharma Letter please login, subscribe or claim a 7 day free trial subscription and access exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space. Or, if you're only interested in reading the content about a specific topic (generics, biosimilars, coronavirus/COVID-19, digital pharma, Asia Pacific), then you can take our £10 per month channel subscription offer, which gives you access to all our news articles and in-depth content on this subject.
Russian pharmaceutical producer partners will invest about RUB4bn ( $ 60 m ) in the full - cycle production of German drug firm Bayer 's anticoagulant Xarelto ( rivaroxaban ) . The two companies previously partnered in collaboration on the production of insulin , Magnevist and Ultravist at mit 's St Petersburg facility . The latest collaboration will also see Polysan 's antiviral drug system developed at the plant .